Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruggero G Fariello

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
SafinamideRuggero G Fariello
Neurology|October 14, 2006
Present and future approaches to Parkinson disease: from molecular insights to new therapeutic avenuesRuggero G Fariello, Abraham Lieberman
European Journal of Pharmacology|March 15, 2005
The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neuronsTina C Stummann, Patricia Salvati, Ruggero G Fariello, et al.
Clinical Neuropharmacology|August 5, 2003
Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibitionCarlo Cattaneo, Carla Caccia, Antonio Marzo, et al.
NPJ Parkinson'S Disease|January 5, 2021
Oleh Hornykiewicz, a giant in the understanding and treatment of Parkinson diseaseLuigi Zecca, Christian Pifl, Stanley Fahn, et al.
Aging and Disease|August 7, 2023
Synergistically Acting on Myostatin and Agrin Pathways Increases Neuromuscular Junction Stability and Endurance in Old MiceRoberta Schellino, Marina Boido, Jan W Vrijbloed, et al.
British Journal of Clinical Pharmacology|November 3, 2012
A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's diseaseDonald E Moss, Ruggero G Fariello, Jörg Sahlmann, et al.
Plos One|March 12, 2020
A new protein curbs the hypertrophic effect of myostatin inhibition, adding remarkable endurance to motor performance in miceMarina Boido, Olena Butenko, Consuelo Filippo, et al.
Neuropharmacology|February 4, 2014
Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic painRuggero G Fariello, Carla Ghelardini, Lorenzo Di Cesare Mannelli, et al.
Pharmacological Research|April 15, 2004
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activityAntonio Marzo, Lorenzo Dal Bo, Nunzia Ceppi Monti, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
SafinamideRuggero G Fariello
Neurology|October 14, 2006
Present and future approaches to Parkinson disease: from molecular insights to new therapeutic avenuesRuggero G Fariello, Abraham Lieberman
European Journal of Pharmacology|March 15, 2005
The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neuronsTina C Stummann, Patricia Salvati, Ruggero G Fariello, et al.
Clinical Neuropharmacology|August 5, 2003
Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibitionCarlo Cattaneo, Carla Caccia, Antonio Marzo, et al.
NPJ Parkinson'S Disease|January 5, 2021
Oleh Hornykiewicz, a giant in the understanding and treatment of Parkinson diseaseLuigi Zecca, Christian Pifl, Stanley Fahn, et al.
Aging and Disease|August 7, 2023
Synergistically Acting on Myostatin and Agrin Pathways Increases Neuromuscular Junction Stability and Endurance in Old MiceRoberta Schellino, Marina Boido, Jan W Vrijbloed, et al.
British Journal of Clinical Pharmacology|November 3, 2012
A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's diseaseDonald E Moss, Ruggero G Fariello, Jörg Sahlmann, et al.
Plos One|March 12, 2020
A new protein curbs the hypertrophic effect of myostatin inhibition, adding remarkable endurance to motor performance in miceMarina Boido, Olena Butenko, Consuelo Filippo, et al.
Neuropharmacology|February 4, 2014
Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic painRuggero G Fariello, Carla Ghelardini, Lorenzo Di Cesare Mannelli, et al.
Pharmacological Research|April 15, 2004
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activityAntonio Marzo, Lorenzo Dal Bo, Nunzia Ceppi Monti, et al.
Pageof 2